Lycopene and resveratrol pretreatment did not interfere with the liver of hepatectomized rats.

Autor: Barros PP; PhD, Full Professor, Researcher, Faculty of Pharmaceutical Sciences, Pontifícia Universidade Católica de Campinas (PUC-Campinas), Brazil. Conception of the study, interpretation of data., Gonçalves GM; PhD, Full Professor, Researcher, Faculty of Pharmaceutical Sciences, PUC-Campinas, Brazil. Conception of the study, interpretation of data., Silva GH; PhD, Full Professor, Researcher, Faculty of Pharmaceutical Sciences, PUC-Campinas, Brazil. Conception of the study, interpretation of data., Bastos MC; Graduate student, School of Medicine, FAPIC, PUC-Campinas, Brazil. Interpretation of data., Ramos LN; Graduate student, School of Medicine, FAPIC, PUC-Campinas, Brazil. Interpretation of data., Fernandes MM; Graduate student, School of Medicine, FAPIC, PUC-Campinas, Brazil. Interpretation of data.
Jazyk: angličtina
Zdroj: Acta cirurgica brasileira [Acta Cir Bras] 2017 Mar; Vol. 32 (3), pp. 194-202.
DOI: 10.1590/S0102-865020170030000003
Abstrakt: Purpose:: To investigate the effects of lycopene and resveratrol pretreatment on hepatic hyperplasia in partially hepatectomized rats.
Methods:: The lycopene group and the resveratrol group received 40 mg/kg/day of lycopene or resveratrol, respectively (dissolved in olive oil or in saline solution, respectively) and administered via a gastric tube for 30 days. The partially hepatectomzed (PH) control groups received saline or olive oil via a gastric tube for 30 days, respectively, and the normal control group received no treatment. Liver tissue and intracardiac blood samples were obtained 24, 36 or 48 h after PH.
Results:: No areas of fibrosis were detected. No significant changes in mitotic index, in the number of apoptosis events or in aspartate aminotransferase and alanine aminotransferase levels were observed.
Conclusions:: Lycopene and resveratrol pretreatment did not interfere on hepatic hyperplasia in partially hepatectomized rats.
Databáze: MEDLINE